Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by stockbuphoonon Jun 19, 2021 11:46pm
212 Views
Post# 33417500

Ad hominem

Ad hominem You think that Thomson is a swing day trader like you and is not burying 4050? Guess you made lots of money on the $7 to $4 short over the last week? Thomson  took years to decide on next phase 2 candidate of 4050 as IPF when markets for kidney and liver were huge and results strong - as in "penicillin" as quoted by Laurin and Moran. So, you're saying they lied and Pritchard is telling the truth? Ryplazim? They spent $100's of millions for $70M from PRV and $5M for plasma division which include IVIG and many others. Sure, kid. Can you quote anything from foundational value argument of any analyst? Didn't think so..
 
<< Previous
Bullboard Posts
Next >>